<SEC-DOCUMENT>0001213900-22-001636.txt : 20220112
<SEC-HEADER>0001213900-22-001636.hdr.sgml : 20220112
<ACCEPTANCE-DATETIME>20220111214612
ACCESSION NUMBER:		0001213900-22-001636
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220112
FILED AS OF DATE:		20220112
DATE AS OF CHANGE:		20220111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		22525401

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea153882-6k_immuronlimit.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Month of January 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: 001-38104</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>IMMURON
LIMITED</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Level
3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&ldquo;Yes&rdquo; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXPLANATORY
NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (the &ldquo;Company&rdquo;) published one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange
on January 12, 2022 titled:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron
                                            awarded A$6.2 million US DoD funding for Travelan&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Public Notice is attached as an exhibit to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report on Form 6-K (including the exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities
Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ea153882ex99-1_immuronlimit.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
    awarded A$6.2 million US DoD funding for Travelan</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
    LIMITED</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 75px; width: 65px"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;January
    12, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Phillip Hains</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip
    Hains</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
    Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea153882ex99-1_immuronlimit.htm
<DESCRIPTION>IMMURON AWARDED A$6.2 MILLION US DOD FUNDING FOR TRAVELAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
Awarded $6.2 Million to Clinically Evaluate a Military Strength Dosing Regimen for Travelan </B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Key
Highlights:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for Travelan</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>U.S
Naval Medical Research Center Received AU $1.4 </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(USD
$1.02) million funding to support the Travelan clinical development effort</FONT></B></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
Award AU $6.2 (USD $4.45) million to examine a dosing regimen for Travelan more suited for use by the military</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plans
in place to conduct a controlled human infection model (CHIM) clinical trial in 60 healthy volunteers in the USA</B></FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
Australia, January 12, 2022: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing
and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding
of a new research agreement with the U.S Department of Defense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
focus of this new agreement, entitled &ldquo;Biologics License Application (BLA) of a therapeutic Bovine Immunoglobulin supplement targeting
Travelers&rsquo; Diarrhea caused by Enterotoxigenic Escherichia Coli (ETEC)&rdquo;, is aimed at testing and confirming the efficacy of
a single larger dose regimen of Travelan&reg; in a controlled human infection model (CHIM) clinical study using the enterotoxigenic <I>Escherichia
coli</I> (ETEC) strain H10407. This single larger dosing regime is potentially more amenable for use in military populations. Up to 60
volunteers will be enrolled in the clinical study and will be randomly assigned to receive either a once-daily dose of 1200 mg of Travelan&reg;
or placebo. This study will occur across two cohorts (n=15 Travelan&reg; subjects and n=15 placebo subjects per cohort), as the inpatient
unit can accommodate up to 30 study participants at a time. Results of the proposed clinical study will also inform on dosing in the
pivotal Phase 3 registration trials for BLA licensure. A project kickoff meeting for this award has been scheduled for the end of January
with the U.S Government sponsors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed development program is based on the past commercial and clinical trial experience with Travelan&reg;. Two company sponsored
clinical studies have demonstrated that Travelan&reg; conferred 84% to over 90% protective efficacy against moderate to severe diarrhea
upon challenge with ETEC in comparison to a placebo. These clinical studies were performed using two different doses of Travelan&reg;
(200 mg and 400 mg), administered 3 times a day. Ongoing discussions with Army and Navy leadership have highlighted that such a regimen
is cumbersome for military personnel deployed in austere environments and military field studies have shown that compliance is low with
products dosed more than once per day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
new project expands our clinical development program and represents the first of several significant clinical trials which the company
expects to undertake with the US Military in 2022. The NMRC plans to clinically evaluate the protective efficacy of our new oral therapeutic
targeting Campylobacter and ETEC this year in two controlled human infection-model clinical trials, with one trial focusing on the ability
of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis, and the second trial focusing on ETEC
infections&rdquo; <B>said Dr. Jerry Kanellos, CEO of Immuron. </B>&ldquo;The new funding is testament to the value proposition our hyperimmune
bovine polyclonal colostrum technology offers to benefit the U.S. Military as well as the civilian international travelling population.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infectious
diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity
and associated discomfort stemming from diarrhea decreases daily performance, affects judgment, decreases morale and declines operational
readiness. The first line of treatment for infectious diarrhea is the prescription of antibiotics. Unfortunately, in the last decade,
several enteric pathogens have an increasing resistance to commonly prescribed antibiotics. In addition, travelers' diarrhea is now recognized
by the medical community to result in post-infectious sequelae, including post-infectious Irritable Bowel Syndrome and several post-infectious
autoimmune diseases. A preventative treatment that protects against enteric diseases, is a high priority objective for the US Military.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release has been authorised by the directors of Immuron Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; width: 31%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3, 62 Lygon Street,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton South, Victoria</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AUSTRALIA 3053</P></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 33%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>www.immuron.com</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABN: 80 063 114 045</P></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 36%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Phone: + 61 (0)3 9824 5254</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Facsimile: + 61 (0)3 9822 7735</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 40px; width: 130px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
                                            CONTACT:</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr
    Jerry Kanellos, Ph.D.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
+61 (0)3 9824 5254</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@immuron.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 37%; font-size: 10pt; text-underline-color: black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 31%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immuron</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelan&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan&reg;
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan&reg; is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia,
Travelan&reg; is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk
of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is
a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan&reg;
is sold as a dietary supplement for digestive tract protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelers&rsquo; diarrhea</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelers&rsquo;
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,
bloating and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing
a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: http://www.immuron.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Page 2 of 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MP  +" !+ $$! 1$ _\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H " $!   _ /9J**AN)1"JLY 0L%)/;/ _7%2CI2T444445!>VZW=I
M+ PRLBE?\/UJ#1M0&I:5!<$%9""DBGJKJ<,#^(-7J******0U@0L='\620.<
M6FJ@RP_[,ZCYU_X$H##_ '6K?!S0#2T44445EZ_I;ZKI<D4#B*ZC(FMI?^><
MJ\J?IG@^Q-+H6KIK.D0W>WRY3E)HCUBE4X=#]"#45G=O-XLU&W$A,4%M!\F?
MNLQD.?Q %;%%%%%)2'H:Y+4+R#P?XC-[=2+#I&K'$K'I%<@<-@<_.HP?=1ZU
MB^'?'&D'Q=XFNKJYDBBDDA2-G@< !%(P>..<GG'6NTA\3Z+<+"T6J6;"8@1_
MO1ER3C@=^:T]X]_RIU(3BJ&IZ[INC1A]2O(;<'[H=OF;Z#J:R$\92WY T?0=
M4O%/262,01G\7(/Z5(=1\4RYV:'80KGK-?9/Y*I_G7%ZG8Z_XETJYUN^328H
MGCVV>XR.\.&^5HQP-SM@@GGD"LGX=VFLZEKFIVQUEK.2=/-OC! C.90[*58M
M]ULDG(%>E:5X#T32[I;P6YNKX'/VJZ;S) ?49X'X 5T&SW-.)Q7,SZQ>Z]=R
MV/AYEBMXCLN-39=RJW=(A_$P]>@]ZNZ1X5TW26:98VN;USF2[N3YDKG_ 'CT
M^@P*V<5'<1>;;2QY*[T*Y';(K TK0K]8["+5IK9H-.51!%;JP#LHPKN2>PZ
M=^?2L#PUIS6?Q=\2B+"P-%'.1W+2 ?ID-7H5+6'XJ&HS:<EGIELTQNY/)F=9
M?+\J,@Y;=U'8<<\U<T:Q;3=-AM7>-O+& (DV(@[*H]![\GO5_%+248%<M8;4
M^*&K*%^9]-MW+?1W%=5128HP!2T445B0Z=.OC>XU';_HTFGQP[L]761SC\B*
-VZ*******3%+17__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !2 10# 2(  A$! Q$!_\0
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M4G*4%&*<I2BDY+T?]E#_ (.?_P#@GG^T+XCTWP7\4HO'W[*GB76+J*RTV_\
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MG>>%?AMKVO20HWAGQII=IJ5SI'A;4[F&Y\'>.-(O?##BSAU2.0\G$_ F0XC
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MZ)I]MX:_;BTG2='7[)9Z!^UW::=I:1?(+6UT_P",JVUI%%M/R+# B1Q@8"J
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M_3UH]?S4?\$!O^3[[_\ [(AXY_\ 3KX:K^EK_@JJC2?\$\/VL%0$M_PJV[;
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M]8M?RT_\'(W_ !_?LC?[OQ?_ /1?@:OZEJ_"/_@M%^PS^TE^V5<_L]R_L_\
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MUF*\@TOQUX?LM32VU?25^(/V*/BUH/@JU_:>_P""0GQR\6)X*O-7C^+7A/\
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MAZ=#(^'<-2HSJ1]IA:-2<JF'HU:L*$E3PWMJU:EBZ\_R4_X-O/\ D8OVL?\
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M+P[XM\(:-X3_ &9-4\97WB_P_K46LMXB\11^)(K!+1/#;V-G-IJ/;FT<W/\
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M!1XK6+P]2@\=Q=G^/P?/R?[1@\52RV.'Q$.6I/\ =UG1JJ'/R3]R7-3CI?\
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  = %X# 2(  A$! Q$!_\0
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CAW-O$O%KZO3IU*U2I5<\(L%5HU</"C"G7]I2IPG[&?\ _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
